Breakthrough invasive fungal infections: Who is at risk?

The epidemiology of invasive fungal infections (IFIs) in immunocompromised individuals has changed over the last few decades, partially due to the increased use of antifungal agents to prevent IFIs. Although this strategy has resulted in an overall reduction in IFIs, a subset of patients develop bre...

Full description

Saved in:
Bibliographic Details
Published in:Mycoses 2020-10, Vol.63 (10), p.1021-1032
Main Authors: Jenks, Jeffrey D., Cornely, Oliver A., Chen, Sharon C.‐A., Thompson, George R., Hoenigl, Martin
Format: Article
Language:English
Subjects:
Antifungal agents
breakthrough fungal infections
Epidemiology
Fungal infections
Morbidity
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The epidemiology of invasive fungal infections (IFIs) in immunocompromised individuals has changed over the last few decades, partially due to the increased use of antifungal agents to prevent IFIs. Although this strategy has resulted in an overall reduction in IFIs, a subset of patients develop breakthrough IFIs with substantial morbidity and mortality in this population. Here, we review the most significant risk factors for breakthrough IFIs in haematology patients, solid organ transplant recipients, and patients in the intensive care unit, focusing particularly on host factors, and highlight areas that require future investigation.
ISSN:0933-7407
1439-0507
DOI:10.1111/myc.13148